JMP Securities lowered the firm’s price target on Aura Biosciences (AURA) to $21 from $23 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AURA:
- Aura Biosciences Reports Q3 Financial Results
- Aura Biosciences reports Q3 EPS (42c), consensus (44c)
- Aura Biosciences price target raised to $23 from $20 at Scotiabank
- Aura Biosciences price target raised to $24 from $21 at BTIG
- Aura Biosciences price target raised to $22 from $21 at H.C. Wainwright